Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Frostman who wrote (8075)	5/15/1998 10:01:00 AM
From: DaiS	Read Replies (1) \| Respond to of 23519

Antone know why Nexmed is going up yesterday and today, their favourable press release was a couple of days ago. DaiS

To: Frostman who wrote (8075)	5/15/1998 10:05:00 AM
From: E'Lane	Respond to of 23519

Thursday May 14, 11:52 pm Eastern Time Viagra breaks record for most new Rx in 1st month NEWTOWN, Pa., May 14 (Reuters) - Patients obtained 570,000 new prescriptions for Pfizer Inc.'s (PFE - news) impotence drug Viagra in April, the most prescriptions ever for a drug in the United States during its first month on the market, the Scott-Levin prescription drug audit service said Thursday. Viagra generated more new prescriptions than Pfizer's blockbuster hypertension drug, Norvasc, and Warner-Lambert Co.'s (WLA - news) anti-cholesterol drug Lipitor, which Pfizer co-promotes, Scott-Levin said. Four Pfizer products were among the 20 top-selling brand-name drugs dispensed in April, the service added. Lipitor, whose early 1997 launch had been dubbed the most successful in history, had only 26,000 new prescriptions in its first month, Scott-Levin said, paling in comparison to Viagra's performance. Drawing another comparison, Scott-Levin said American Home Products Corp.'s (AHP - news) obesity drug Redux had 149,000 new prescriptions during its first month. Redux was taken off the market last year amid reports of possible heart valve damage in some patients who took the obesity drug. In April, Viagra claimed 95 percent of new prescriptions in the erectile dysfunction market, the audit service said. Vivus Inc.'s (VVUS - news) impotence product MUSE captured 4 percent of new prescriptions, while Pharmacia & Upjohn's (PHU.ST) Caverject had a 1 percent share of the market. Urologists wrote 41 percent of new Viagra prescriptions, while general and family practitioners accounted for 23 percent. Internists (21 percent), cardiologists (2 percent) and general surgeons (1 percent) accounted for most of the remaining new prescriptions, Scott-Levin said. More than 50 percent of Viagra prescriptions were paid for in cash, with the remainder reimbursed by third-party organizations, it added, noting some managed-care plans have adopted stringent guidelines for Viagra reimbursement.